Small-Cap Biotechs

Bad News For Its Competitor Could Be Great News For This Small-Cap Biotech – And Its Shareholders

In January, the small-cap biotech highlighted in today’s article received FDA approval for its treatment for childhood peanut allergy – and with peanut allergy being the most common food allergy in the U.S. (with cases of the condition rising rapidly) and the fact that this is currently the only FDA-approved treatment for the condition (thanks to a competitor encountering some… 

This Under-The-Radar Biotech’s Only Drug Candidate Could Become “A Mega-Blockbuster”

While buying right now may be too risky for the average investor, the small-cap biotech highlighted in today’s article could be worth keeping an eye on, even as it (and many other promising biotech stocks) may have slipped under the radar as attention has shifted to potential COVID-19 plays (which this stock is not). Why? The company’s drug candidate for…